title: Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
authors.affiliation: Michael E. DeBakey Veteran's Affairs Medical Center, Houston, TX, USA. glenn.levine@bcm.tmc.edu
authors.forename: Glenn N
authors.initials: GN
authors.lastname: Levine
authors.forename: Anthony V
authors.initials: AV
authors.lastname: D'Amico
authors.forename: Peter
authors.initials: P
authors.lastname: Berger
authors.forename: Peter E
authors.initials: PE
authors.lastname: Clark
authors.forename: Robert H
authors.initials: RH
authors.lastname: Eckel
authors.forename: Nancy L
authors.initials: NL
authors.lastname: Keating
authors.forename: Richard V
authors.initials: RV
authors.lastname: Milani
authors.forename: Arthur I
authors.initials: AI
authors.lastname: Sagalowsky
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Smith
authors.forename: Neil
authors.initials: N
authors.lastname: Zakai
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000401:mortality; D006801:Humans; D008297:Male; D009017:Morbidity; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D018570:Risk Assessment; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents